SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-151011
Filing Date
2022-05-16
Accepted
2022-05-16 09:04:34
Documents
14
Period of Report
2022-05-16
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d264834d8k.htm   iXBRL 8-K 25215
2 EX-99.1 d264834dex991.htm EX-99.1 44868
6 GRAPHIC g264834g69v50.jpg GRAPHIC 6837
  Complete submission text file 0001193125-22-151011.txt   211486

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mgta-20220516.xsd EX-101.SCH 2863
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mgta-20220516_lab.xml EX-101.LAB 17979
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mgta-20220516_pre.xml EX-101.PRE 11263
8 EXTRACTED XBRL INSTANCE DOCUMENT d264834d8k_htm.xml XML 3341
Mailing Address 100 TECHNOLOGY SQUARE 5TH FLOOR CAMBRIDGE MA 02139
Business Address 100 TECHNOLOGY SQUARE 5TH FLOOR CAMBRIDGE MA 02139 857-201-2700
Magenta Therapeutics, Inc. (Filer) CIK: 0001690585 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38541 | Film No.: 22925874
SIC: 2834 Pharmaceutical Preparations